Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

NDA FilingALXN1840Positive

AI Analysis

Summary

Monopar Therapeutics initiated a rolling NDA submission for ALXN1840 in Wilson Disease, a significant regulatory milestone in the drug development process.

Outcome Details

Rolling NDA submission initiated

Importance:7/10

Sentiment:

0.60

NDA filingWilson Diseaseregulatory milestonerolling submission

Related Companies

$MNPR

Read the original article

Published by Drugs.com Clinical Trial Results on July 22, 2026 9:07 PM

Read Original